CDRT15P9

Across TCGA pan-cancer cohorts, CDRT15P9 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated CDRT15P9 data layer.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CDRT15P9 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CDRT15P9 expression acts as an unfavorable survival marker, although some lineages such as LGG and DLBC show a favorable association.

LGG, LIHC, and CHOL are the cancer types where CDRT15P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Tertile	All	0.504	0.311	<.001	46	view →
LIHC	OS	Quartile	All	0.567	0.759	.002	32	view →
CHOL	DFS	Median	All	0.127	0.679	.002	18	view →
HNSC	OS	Quartile	III,IV	0.524	0.726	.008	15	view →
UCEC	DFS	Quartile	All	0.851	0.923	.014	12	view →
DLBC	DFS	Median	All	1.000	0.376	.011	9	view →
KIRC	DFS	Quartile	III,IV	0.401	0.573	.040	6	view →
UCS	OS	Tertile	III,IV	0.375	0.741	.040	6	view →
ACC	DFS	Median	IV	0.518	0.217	.016	6	view →
LUAD	DFS	Quartile	III,IV	0.465	0.212	.038	5	view →
KICH	OS	Tertile	All	0.962	0.831	.039	4	view →
BRCA	OS	Median	IV	0.188	0.566	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

CDRT15P9–LGG (DFS)

Open the LGG breakdown →